Hikal

how big is Hikal?

As of October 2023, Hikal Ltd has a market capitalization of 4,609.00 Cr, with recent net sales of 1,859.80 Cr and a net profit of 90.80 Cr over the last four quarters. Shareholder's funds are 1,187.66 Cr, and total assets amount to 2,487.15 Cr as of March 2024.

Market Cap: Hikal Ltd has a market capitalization of 4,609.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 1,859.80 Cr. The sum of Net Profit for the same period is 90.80 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 1,187.66 Cr, while Total Assets amount to 2,487.15 Cr.

What is the bonus history of the Hikal?

Hikal Ltd announced a 1:2 bonus issue on June 22, 2018, with a record date of June 25, 2018, meaning shareholders received one additional share for every two shares held.

Hikal Ltd has a bonus history that includes a 1:2 bonus issue announced on June 22, 2018. The record date for this bonus was June 25, 2018. This means that for every two shares held, shareholders received one additional share as a bonus.

Has Hikal declared dividend?

Hikal Ltd has declared a 30% dividend, amounting to ₹0.6 per share, with an ex-date of February 7, 2025. The company has shown varying performance, achieving a total return of 205.88% over the last 5 years, making it appealing for income-focused investors.

Hikal Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 0.6<BR>- Ex-date: 07 Feb 25<BR><BR>Dividend Yield: 0.32%<BR><BR>Total Returns by Period:<BR>In the last 6 months, Hikal Ltd experienced a price return of -14.83%, a dividend return of 0.14%, resulting in a total return of -14.69%.<BR><BR>Over the past year, the company saw a price return of 30.19%, a dividend return of 0.40%, leading to a total return of 30.59%.<BR><BR>In the 2-year period, Hikal Ltd had a price return of 14.57%, a dividend return of 0.74%, which culminated in a total return of 15.31%.<BR><BR>For the 3-year period, the price return was 25.58%, with a dividend return of 1.49%, resulting in a total return of 27.07%.<BR><BR>During the 4-year period, the company experienced a price return of -15.79%, a dividend return of 1.17%, leading to a total return of -14.62%.<BR><BR>In the last 5 years, Hikal Ltd achieved a remarkable price return of 200.48%, a dividend return of 5.40%, culminating in a total return of 205.88%.<BR><BR>Overall, Hikal Ltd has declared a dividend and demonstrated varying performance across different periods, with significant total returns over the long term, particularly in the 5-year span. The recent dividend declaration adds to the appeal for investors looking for income alongside capital appreciation.

Who are the peers of the Hikal?

Hikal's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Aarti Drugs, Dishman Carbogen, Unichem Labs, and Gufic BioScience. In terms of performance, Divi's Lab leads with a 1-year return of 51.69%, while Hikal has a return of 31.90%.

Peers: The peers of Hikal are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Aarti Drugs, Dishman Carbogen, Unichem Labs., and Gufic BioScience.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Aarti Drugs, and Gufic BioScience, while Good management risk is found at Divi's Lab., Torrent Pharma, Hikal, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Hikal, Aarti Drugs, Dishman Carbogen, and the rest. In terms of Capital Structure, Excellent ratings are given to Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Average is noted for Hikal, and Good for Torrent Pharma, Aarti Drugs, Unichem Labs., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Aarti Drugs at -3.71%. Hikal's own 1-year return is 31.90%, which is significantly higher than Aarti Drugs but lower than Divi's Lab. Additionally, Dishman Carbogen, Unichem Labs., and Gufic BioScience have negative six-month returns.

Who are in the management team of Hikal?

As of March 2023, Hikal's management team includes Jai Hiremath (Executive Chairman), Sameer Hiremath (Managing Director), and several non-executive and independent directors, overseeing the company's operations and strategic direction.

As of March 2023, the management team of Hikal includes the following individuals:<BR><BR>1. Jai Hiremath - Executive Chairman<BR>2. Sameer Hiremath - Managing Director<BR>3. Baba Kalyani - Non-Executive & Non-Independent Director<BR>4. Kannan Unni - Non-Executive & Independent Director<BR>5. Sugandha Hiremath - Non-Executive & Non-Independent Director<BR>6. Prakash V Mehta - Non-Executive & Independent Director<BR>7. Amit B Kalyani - Non-Executive & Non-Independent Director<BR>8. Ranjit Shahani - Non-Executive & Independent Director<BR>9. Shivani Bhasin Sachdeva - Non-Executive & Independent Director<BR>10. Rajasekhar Reddy - Company Secretary & Compliance Officer<BR>11. Shrikrishna K. Adivarekar - Independent Director<BR>12. Berjis Minoo Desai - Independent Director<BR>13. V R Kaundinya - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Hikal do?

Hikal Ltd is a small-cap company in the Pharmaceuticals & Biotechnology sector, specializing in chemical intermediates, specialty chemicals, and active pharma ingredients. As of March 2025, it reported net sales of ₹5,524 Cr and a net profit of ₹502 Cr, with a market cap of ₹4,278 Cr.

Overview:<BR>Hikal Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, engaged in the manufacturing of chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities.<BR><BR>History:<BR>Hikal Ltd was incorporated on July 8, 1988. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 5,524 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 502 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 4,278 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 47.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.34% <BR>Debt-Equity: 0.59 <BR>Return on Equity: 7.19% <BR>Price-to-Book: 3.40 <BR><BR>Contact Details:<BR>Address: 717/718 Maker Chamber V, 7th Floor Nariman Point Mumbai Maharashtra : 400021 <BR>Tel: 91-022-3926 7100/62770477 <BR>Email: secretarial@hikal.com/info@hikal.co <BR>Website: http://www.hikal.com

Who are the top shareholders of the Hikal?

The top shareholders of Hikal include Kalyani Investment Company Limited with 31.36%, followed by 76 Foreign Institutional Investors holding 5.69%, and mutual funds with a combined 2.93%. Individual investors own 16.57%, with Tata Mutual Fund - Tata Small Cap Fund being the largest public shareholder at 2.68%.

The top shareholders of Hikal include the promoters, who hold the majority of the shares. The promoter with the highest holding is Kalyani Investment Company Limited, which owns 31.36% of the company. Additionally, there are 76 Foreign Institutional Investors (FIIs) holding 5.69%, and mutual funds are represented by 7 schemes with a combined holding of 2.93%. The highest public shareholder is Tata Mutual Fund - Tata Small Cap Fund, which holds 2.68%. Individual investors collectively own 16.57% of the shares.

Are Hikal latest results good or bad?

Hikal's latest results are disappointing, with a significant decline in profitability and key metrics, including a PBT of Rs -31.40 crore and a PAT of Rs -22.40 crore. Net sales fell by 18.2%, indicating serious challenges and a negative outlook for the company.

Hikal's latest financial results for the quarter ending June 2025 indicate a disappointing performance. The company reported a significant decline in key metrics, with a financial score dropping to -14 from 23 over the past three months, which reflects a negative trend.<BR><BR>In terms of profitability, both Profit Before Tax (PBT) and Profit After Tax (PAT) saw substantial declines, with PBT falling to Rs -31.40 crore and PAT decreasing to Rs -22.40 crore. This represents a drop of 205.7% and 198.7%, respectively, compared to the averages of the previous four quarters. <BR><BR>Net sales also decreased, totaling Rs 380.40 crore, which is an 18.2% decline from the prior four-quarter average. The company’s operating profit margins and earnings per share have reached their lowest levels in five quarters, indicating deteriorating efficiency and profitability. Additionally, cash and cash equivalents have declined to Rs 18.00 crore, suggesting worsening short-term liquidity.<BR><BR>While Hikal has managed to reduce its debt-equity ratio to 0.61, the overall financial results reflect significant challenges and a negative outlook for the company.

When is the next results date for Hikal?

The next results date for Hikal is 13 November 2025.

The next results date for Hikal is scheduled for 13 November 2025.

How has been the historical performance of Hikal?

Hikal's historical performance shows mixed results, with net sales peaking at 2,023.03 Cr in Mar'23 before declining to 1,859.80 Cr in Mar'25, while operating profit increased slightly to 333.40 Cr in Mar'25, despite decreases in profit before and after tax. Total assets and liabilities rose to 2,528.90 Cr in Mar'25, and cash flow from operating activities improved to 280.00 Cr.

Answer:<BR>The historical performance of Hikal shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Hikal's net sales have fluctuated, with a peak of 2,023.03 Cr in Mar'23, followed by a decline to 1,859.80 Cr in Mar'25. The total operating income mirrored this trend, reaching 2,023.03 Cr in Mar'23 and decreasing to 1,859.80 Cr in Mar'25. Raw material costs rose to 882.60 Cr in Mar'25 from 781.90 Cr in Mar'20, while total expenditure (excluding depreciation) decreased to 1,531.40 Cr in Mar'25 from 1,765.96 Cr in Mar'23. Operating profit (PBDIT) saw a slight increase to 333.40 Cr in Mar'25 from 262.48 Cr in Mar'23, although profit before tax dropped to 123.80 Cr in Mar'25 from 105.37 Cr in Mar'23. Profit after tax also decreased to 90.80 Cr in Mar'25 from 78.39 Cr in Mar'23. The company's total assets increased to 2,528.90 Cr in Mar'25 from 2,385.48 Cr in Mar'23, while total liabilities rose to 2,528.90 Cr in Mar'25 from 2,385.48 Cr in Mar'23. Cash flow from operating activities improved to 280.00 Cr in Mar'25 from 186.00 Cr in Mar'24, indicating a positive trend in cash generation. Overall, Hikal's financial performance reflects both challenges and improvements across various metrics over the years.

Should I buy, sell or hold Hikal?

Is Hikal technically bullish or bearish?

As of December 3, 2025, Hikal's technical trend is mildly bearish, with mixed signals from indicators like the MACD and Bollinger Bands, suggesting a cautious outlook in the short term.

As of 3 December 2025, the technical trend for Hikal has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The Bollinger Bands and moving averages are both mildly bearish on the weekly and daily time frames. The KST shows a mildly bullish signal on the weekly, while the monthly remains bearish. The Dow Theory also reflects a mildly bullish stance on the weekly but is bearish on the monthly. Overall, the indicators suggest a cautious outlook with a slight bearish bias in the short term.

Is Hikal overvalued or undervalued?

As of December 4, 2025, Hikal's valuation has shifted from attractive to fair, with a high PE ratio of 309.11 and significant underperformance at -35.04% year-to-date, indicating concerns about its growth prospects compared to peers like Sun Pharma and Cipla.

As of 4 December 2025, Hikal's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 309.11, an EV to EBITDA of 16.62, and a Price to Book Value of 2.61. In comparison to peers, Sun Pharma has a PE ratio of 37.78 and an EV to EBITDA of 24.99, while Cipla is rated attractive with a PE of 22.58 and an EV to EBITDA of 15.98, highlighting Hikal's significant overvaluation relative to its competitors.<BR><BR>Despite its fair valuation, Hikal has underperformed in the market, with a year-to-date return of -35.04% compared to the Sensex's 9.12%. This underperformance, coupled with a high PEG ratio of 0.00 and low ROE of 0.85%, suggests that investors may be cautious about the company's growth prospects moving forward.

Which are the latest news on Hikal?

Why is Hikal Ltd falling/rising?

As of 01-Feb, Hikal Ltd's stock price is Rs. 190.75, down 1.14%, having hit a 52-week low. The company has seen a 45.06% decline in stock value over the past year, compounded by poor financial performance and negative market sentiment.

As of 01-Feb, Hikal Ltd's stock price is falling, currently at Rs. 190.75, reflecting a decrease of Rs. 2.2 or 1.14%. The stock has recently hit a new 52-week low of Rs. 188.2, indicating significant downward pressure. Over the past week, the stock has underperformed the benchmark Sensex, declining by 1.68% compared to the Sensex's 1.00% drop. In the past month, Hikal Ltd has experienced a substantial decline of 16.21%, while the Sensex fell only 4.67%. <BR><BR>The company's performance over the last year has been particularly poor, with a staggering 45.06% decrease in stock value, contrasting sharply with the Sensex's gain of 5.16%. This trend is compounded by a weak long-term fundamental outlook, evidenced by a -16.24% compound annual growth rate (CAGR) in operating profits over the last five years and a high debt to EBITDA ratio of 2.51 times, indicating low ability to service debt.<BR><BR>Additionally, the company has reported negative results for the last two consecutive quarters, with a significant fall in profit after tax (PAT) of -320.5% compared to the previous four-quarter average. The return on capital employed (ROCE) is also low at 4.1%, further highlighting the company's struggles. The declining investor participation, with a 25.68% drop in delivery volume against the five-day average, suggests diminishing interest from investors.<BR><BR>Overall, these factors contribute to the stock's decline, reflecting a combination of poor financial performance, negative market sentiment, and weak operational fundamentals.